Fulcrum Therapeutics, Inc. (FULC) Stock

Fulcrum Therapeutics, Inc. (FULC) is a Healthcare stock trading at $3.70 (as of 2026-06-18), with a market capitalization of $461.10M and a trailing P/E of -3.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for genetically defined diseases with significant unmet needs in the United States. Its pipeline includes losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease and other hemoglobinopathies, while it also identifies drug targets and has collaborations with Acceleron Pharma and MyoKardia.

Valuation — source: SEC EDGAR (first-party)
Price	$3.70
Market Cap	$461.10M
P/E Ratio	-3.2
EV / EBITDA	-2.3
Price / Book	0.74
DCF Value (model)	$-12.47
DCF Upside vs Price	-437.0%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-22.8%
Current Ratio	34.33
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	637.5%
FCF Growth (YoY)	2319.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	6.65 (safe)

Valuation vs Sector & Industry
Stock P/E	-3.2
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-115.4%
vs Industry	-118.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	SUVRETTA CAPITAL MANAGEMENT, LLC ($50.32M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Alexander C. Sapir
Employees	45
Country	US
IPO Date	2019-07-18

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.